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On the following pages you will find four documents: 
 
1)  A Patient Handout on the several “dangerous” drugs that have been highlighted in the 
Toronto Star and U.S. news since the FDA official told Congress about them.  This Patient 
Handout covers Celebrex, Crestor (the statins), and several others. 
2)  A Patient Handout on JUST the COX-2 inhibitors and naproxen for you to use if patients are 
asking about only these.   
3)  A Health Canada Advisory on COX-2 inhibitors. 
4)  Professional Information for you covering all of these drugs. 
 
You may use your choice of either (or both) of the Patient Handouts to suit your needs.  Active 
subscribers have our permission to reproduce copies of the Patient Handouts for you to hand to 
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The removal from the market of the painkillers Vioxx (rofecoxib) and Bextra (valdecoxib), 
because of the possibility that they cause heart attacks and strokes, has led people to question the 
safety of other medicines.  A recent report in the Toronto Star newspaper highlighted medicines 
or medicine groups that the writers felt were unsafe.  Additionally, there is some current news 
about Celebrex, which is also a painkiller like Vioxx and Bextra.  You may have heard about 
these as well.  Here is some information to help you understand these medicines. 
 
Cholesterol-lowering medicines-“the statins” 
The cholesterol lowering medicines known as “the statins” (examples include Lipitor, 
Crestor, Zocor, and others) lower levels of bad cholesterol.  While they are very effective at 
lowering cholesterol, they can also rarely cause side effects.  Some of the most severe side 
effects include liver damage and breakdown of muscles which can cause muscle pain and kidney 
damage.  For this reason, your health care professional will order blood tests to check your liver.  
Also, you should call your health care professional if you start to get muscle pain or weakness, 
unusual nausea, abdominal pain, fatigue, dark urine, pain when urinating, pale stools, or yellow-
looking eyes or skin. 
 
Weight-loss medicines – Meridia (sibutramine) and Xenical (orlistat) 
You may have heard about the weight loss medicines called Meridia and Xenical.   
Meridia creates a feeling of fullness, but can also cause high blood pressure and increase the 
heart rate, which can lead to stroke or heart attack.  But those needing to take weight loss 
products like Meridia may already have blood pressure problems.  If you take Meridia, you 
should have your blood pressure and heart rate checked regularly.  Also, people who have had 
heart problems or strokes in the past should not use Meridia. 
Xenical decreases the amount of fat that is absorbed into the body.  But that effect can also 
cause your stool to be oily and loose.  Other side effects are stomach cramping, diarrhea, 
inflammation of the pancreas, and vitamin deficiencies.  If you take Xenical, you should divide 
your daily fat intake evenly over your three main meals and take a multivitamin that contains 
vitamins D, E, K, and beta-carotene.  This multivitamin should be taken at least two hours before 
or after taking your Xenical. 
 
Zyban (bupropion) 
Zyban is a non-nicotine medicine to help people stop smoking.  Zyban reduces the nicotine 
withdrawal symptoms and the urge to smoke.  It is more effective when people also go to a 
patient support program.  However, there is concern about a number of side effects.  Rarely, 
patients who are taking Zyban have had heart attacks.  But, it is hard to tell if they had a heart 
attack because they have heart disease from years of smoking or if the heart attack happened 
because of the Zyban.  Other side effects include thoughts of suicide or suicide attempts and 
seizures.    
If you have had a seizure disorder, eating disorder such as bulimia or anorexia nervosa, or are 
stopping the use of alcohol or sedatives, you should not take Zyban since these conditions may 
increase the chance of seizures.  Also, you should not take more than 150 mg twice a day.  With 
your families help, you should watch for depression or thoughts of suicide or feelings of anxiety, 
irritability, hostility, severe restlessness, overly excited behavior, or not being able to sleep.  
These symptoms should be reported to your health care professional immediately.  Finally, you  
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should check your blood pressure regularly, especially if you are using Zyban with a nicotine 
patch.  
 
The Serotonin Reuptake Inhibitor Antidepressants (SSRIs) 
The SSRI antidepressants (such as Paxil, Prozac and others) are commonly used for anxiety 
and depression as well as many other conditions.  They have been promoted for conditions such 
as weight loss, incontinence, alcoholism, cocaine dependence, migraines, pain, fibromyalgia, 
irritable bowel syndrome, compulsive shopping and many other uses.  These are considered “off-
label” uses or uses for which the medicine has not been officially approved by Health Canada.  
“Off-label” prescribing is common and can be beneficial for many people.  However, recently, 
concern that use of these antidepressants can lead to an increased risk of aggression, violence, 
and suicide has surfaced.  This is even more concerning because the use of these antidepressants 
has skyrocketed, particularly for “off-label” uses.  
If you or a family member are taking an SSRI antidepressant, you should watch for any of the 
following symptoms, and if they occur, report them immediately to your health care provider: 
thoughts of suicide or suicide attempt; new or worsening depression; or anxiety; feeling agitated, 
irritable or panicky; acting aggressively, violently or in a dangerous manner; being extremely 
hyperactive in actions and talking; or any other unusual behavior. 
 
Bextra (valdecoxib) and Celebrex (celecoxib) 
Bextra and Celebrex (celecoxib) are used mainly for arthritis pain, menstrual pain, or other 
pain.  Many experts are concerned that Bextra and Celebrex can lead to an increased chance of 
heart problems or stroke.  Bextra and Celebrex are similar to Vioxx, which was just taken off the 
market due to these types of problems.  As of April 2005, Bextra is no longer available because 
of these problems as well as the severe rash it can cause.  For more information on Bextra’s 
withdrawal go to: 
http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_17.html. 
The chance of a problem in any one patient is very low, but since the problem seems to be 
related to cardiovascular disease, it makes sense to try to avoid Celebrex in patients who have 
heart problems.  
Patients who have heart trouble and are taking Celebrex should talk with their health care 
professional.  
People who are not likely to benefit from Celebrex may be better off on a regular NSAID 
(such as Motrin or Advil or a store’s brand product) or acetaminophen (such as Tylenol or a 
store’s brand product).  Patients should discuss this with their pharmacist and/or physician.   
For more information on Celebrex go to: 
http://www.hc-sc.gc.ca/english/protection/warnings/2004/2004_67_e.html 
http://www.pfizer.ca/english/newsroom/press%20releases/default.asp?s=1&releaseID=149 
Just recently, the FDA issued a patient advisory statement on naproxen (Aleve, Naprosyn) 
which can be bought over-the-counter in the U.S.  Preliminary information from an Alzheimer’s 
disease study showed some evidence of increased risk of cardiovascular events in patients taking 
naproxen.  The FDA advises that patients should not exceed the recommended dose of 220 mg 
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Every medicine has side effects.  Your pharmacist and/or physician know the possible side 
effects of drugs and can carefully weigh the benefit of medicines against their risks.  Your health 
care professional will review possible side effects with you and give you information about how 
to reduce these risks.  Be sure to ask any questions you have when a drug is prescribed or 
dispensed and while you are taking it.  Always follow the medication instructions that your 
health care professional gives you.  Never share medications since this is a very dangerous 
practice.  Be sure to get your medicines from a trusted pharmacist.   
 
If you have any concerns, please feel free to discuss them with your health care professional 







































Information for Patients Taking Celebrex or Naproxen 
 
Celebrex (celecoxib) and naproxen are used mainly for pain such as arthritis pain.  Many patients 
also use them for menstrual pain.  Many experts are now concerned that Celebrex and naproxen 
can lead to an increased chance of heart problems or stroke.  Celebrex is similar to Vioxx and 
Bextra which were taken off the market due to these types of problems.  Naproxen is a regular 
painkiller like Motrin or Advil. 
 
The chance of a problem in any one patient is very low.  It is important to remember that many 
millions of people have used these medicines and many are still using them.  Researchers 
continuously conduct studies to learn more about the drugs.  Recently, researchers were studying 
to see if Celebrex was useful to prevent colon cancer.  During the course of the study researchers 
noticed that there was an increase in heart problems in the people who were taking Celebrex.  
These studies usually run for years and involve many patients.  In this case it requires statistical 
calculations to determine that there was an increase in heart problems in the patients taking 
Celebrex.  Just recently, the FDA issued a patient advisory statement on naproxen (Aleve, 
Naprosyn) which can be bought over-the-counter in the U.S.  Preliminary information from an 
Alzheimer’s disease study showed some evidence of increased risk of cardiovascular events in 
patients taking naproxen.  Any individual patient who has taken Celebrex or naproxen should not 
become overly concerned.  
 
Since the problem seems to be related to cardiovascular disease, it makes sense to try to avoid 
Celebrex in patients who have heart problems. Patients who have heart trouble and are taking 
Celebrex or naproxen should talk with their health care professional to see if some other therapy 
might be better for them.  
 
Bextra, Celebrex, and Vioxx are called COX-2 inhibitor drugs.  These drugs are actually in the 
same family of drugs that are called nonsteroidal anti-inflammatory drugs (NSAIDs).  One of the 
problems with some nonsteroidal anti-inflammatory drugs (NSAIDs) is that they can sometimes 
lead to bleeding in the stomach.  It was thought that the COX-2 drugs such as Bextra, Celebrex, 
and Vioxx would not lead to as much bleeding in the stomach as the other nonsteroidal anti-
inflammatory drugs (NSAIDs).  So patients who had ulcers or other chance of bleeding in the 
stomach or intestinal track often got a drug like Bextra, Celebrex, or Vioxx instead of the regular 
nonsteroidal anti-inflammatory drugs (NSAIDs).  Pharmaceutical firms encouraged physicians to 
use these COX-2 drugs for many people.  Many people might be better off on a regular NSAID 
(such as Motrin, Advil, or a store’s brand product), or acetaminophen (such as Tylenol or a store’s 
brand product).  Patients should not exceed the recommended dose or duration printed on any 
over-the-counter medicine bottle unless a physician directs otherwise.  Patients should discuss 
this with their pharmacist and/or physician.   
 
There was a separate concern related to Bextra.  It could cause severe rash, which in some cases 
was life-threatening.  This reaction was unpredictable, and could happen after short or long 
periods of use.  In April 2005, Health Canada asked Pfizer Canada, the manufacturer of Bextra, to 
voluntarily withdraw Bextra from the market. 
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Safety Information Regarding Selective COX-2 Inhibitor NSAIDs: Vioxx, 
(Rofecoxib), Celebrex (Celecoxib), Bextra (Valdecoxib), Mobicox 
(Meloxicam) and Generic Forms of Meloxicam 
 
 
The following excerpts are reprinted from the 
December 22, 2004 Health Canada Advisory on safety 





Health Canada wishes to inform Canadians of 
safety concerns regarding the group of drugs 
known as selective COX-2 inhibitor NSAIDs 
(non-steroidal anti-inflammatories).  These 
include Vioxx (rofecoxib), which has been 
withdrawn from the market, Celebrex (celecoxib), 
Bextra (valdecoxib), and Mobicox (meloxicam), 
which are used in the treatment of symptoms of 
rheumatoid arthritis, osteoarthritis and primary 
dysmenorrhea (menstrual pain). 
Accumulating evidence indicates that the use 
of selective COX-2 inhibitor NSAIDs, in certain 
individuals, is associated with an increased risk of 
heart attack or stroke when compared to placebo. 
The risk appears to increase with the total daily 
dose and the length of the treatment.  However, 
given the available data, it is not possible to 
identify which patients would present a higher 
risk of heart attack and stroke. 
Health Canada has requested additional safety 
information from the manufacturers of Celebrex, 
Bextra, Mobicox and generic forms of meloxicam, 
and will continue to review the safety profile of 
these drugs in order to fully consider what is 
presently known about the risks and benefits of 
these drugs when used according to their 
labelling. 
Until further information from long-term 
clinical trials becomes available, one should 
consider that there is a strong possibility of an 
increased risk of cardiovascular events, including 
heart attack and stroke, when using selective 
COX-2 inhibitor NSAIDs (Celebrex, Bextra, 
Mobicox, and all generic forms of meloxicam). 
Patients should discuss the benefits and risks 
of treatment options with their physician, in light 
of the following information.  
 
Vioxx (rofecoxib) 
Vioxx was withdrawn on September 30, 2004, 
based on new safety information from a three-
year, randomized double-blind clinical trial, called 
APPROVe, showing a possible increased risk of 
cardiovascular events.  The APPROVe 
(Adenomatous Polyp Prevention on VIOXX) 
clinical trial was designed to assess the 
effectiveness of 25 mg Vioxx in preventing the 
recurrence of colon polyps (abnormal tissue 
growth, which may or may not be cancerous).  In 
the APPROVe trial, Vioxx was compared to a 
placebo (sugar pill).  Merck & Co withdrew Vioxx 
from the worldwide market after the study 
indicated an increased risk of serious 
cardiovascular events, such as heart attacks and 
strokes, after 18 months of continuous treatment. 
 
Bextra (valdecoxib) 
On December 10, 2004, Pfizer Inc. released 
new information about cardiovascular risks 
associated with Bextra. In a study conducted by 
Pfizer, which included over 1,500 patients treated 
for acute pain after coronary artery bypass 
grafting (CABG), an increased risk of 
cardiovascular events was observed in patients 
treated with Bextra compared to placebo.  These 
cardiovascular events included myocardial 
infarction (heart attack), cerebrovascular accident 
(stroke), deep vein thrombosis (blood clots in the 
leg), and pulmonary embolism (blood clot in the 
lung).  The risk of these effects was observed to 
be greater with the intravenous form of the drug 
(Detail-Document #210116) 
 
(approximately two percent of patients had such 
an adverse event), in comparison with the oral 
form of the drug (approximately 1 percent of 
patients), immediately following CABG surgery. 
About 0.5 percent of patients taking the placebo 
had an adverse cardiovascular event.  
 
Celebrex (celecoxib) 
On December 17, 2004, the National Cancer 
Institute (NCI) in the United States announced 
that it had stopped a three-year Celebrex study 
called Adenoma Prevention with Celecoxib 
(APC) due to an interim analysis showing a 
statistically significant increase in the risk of heart 
attack, stroke and cardiovascular death.  Health 
Canada has withdrawn market authorization for 
the use of Celebrex for the prevention of 
recurrence of Familial Adenomatous Polyposis, 
which is predictive of colorectal cancer. Celebrex 
should not be taken for the prevention of 
recurrence of Familial Adenomatous Polyposis 
and patients should discuss alternative therapeutic 
options with their doctors. 
 
Background on Selective COX-2 Inhibitor 
NSAIDs 
Selective COX-2 inhibitor NSAIDs were first 
authorized for sale in Canada in 1999 based on 
data showing a better gastrointestinal safety 
profile than traditional (non-selective) NSAIDs 
(for example, ibuprofen).  There was a need for 
new therapies because of the well-documented 
frequent and severe gastrointestinal adverse 
events (for example ulcers and gastric 
haemorrhages) associated with the use of 
traditional (non-selective) NSAIDs.  Also, a 
significant number of patients could not tolerate 
traditional (non-selective) NSAIDs because of 
stomach upset.  
It should be noted that alternative therapies to 
selective COX-2 inhibitor NSAIDs also present 
risks.  Therefore, patients should discuss with 
their physician all benefits and risks of selective 
COX-2 inhibitor NSAIDs versus alternative 
therapies, in order to determine the most 





Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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Professional Information 
“Dangerous Medications” - Preventing Serious Side Effects 
Lead authors: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor 
and Neeta Bahal O’Mara, Pharm.D., BCPS 
 
Background 
The recent removal of the painkiller, Vioxx 
(rofecoxib) because of the possibility that it 
causes heart attacks and strokes has led people to 
question the safety of other medicines.1   
On November 18, 2004, Dr. David Graham 
testified before the U.S. Senate Committee on 
Finance.  Dr. Graham is the Associate Director for 
Safety, Office of Drug Safety for the Food and 
Drug Administration.  In his presentation made at 
the hearing on FDA, “Merck and Vioxx: Putting 
Patient Safety First,” he identified five FDA-
approved “dangerous drugs.”  These include the 
diet drug Meridia (sibutramine), the cholesterol 
drug Crestor (rosuvastatin), the acne medication 
Accutane (isotretinoin), the anti-inflammatory 
drug Bextra, and the asthma medicine Serevent 
(salmeterol).1  The risks associated with these 
FDA-approved products that Dr. Graham 
identified are well known.  The larger concern is 
that there may be system problems in checks and 
balances for rapid drug approval versus safety 
assurance.    
Similarly, a recent report in the Toronto Star 
newspaper highlighted medicines or medicine 
groups that the writers felt were unsafe.2-6   The 
risks associated with these products are well- 
known and can often be minimized.   
 
Minimizing “Dangerous Drug” Effects 
Appropriate prescribing, dispensing, 
administration, and monitoring of medication use 
are essential for assurance of patient safety.   
The HMG-CoA reductase inhibitors or 
“statins” such as Lipitor (atorvastatin), Zocor 
(simvastatin), or Crestor (rosuvastatin) can cause 
rhabdomyolysis or hepatotoxicity.  Patients should 
report any muscle pain or weakness as well as any 
signs of liver problems such as yellow skin or 
sclera.  Liver function tests should be routinely 
monitored and the medication should be stopped 
if the AST or ALT increases to greater than three 
times the upper limit of normal. 
The consumer advocacy group, Public Citizen, 
has specifically admonished Crestor for causing 
kidney damage and rhabdomyolysis.  In general, 
the risk of rhabdomyolysis is higher with higher 
doses.  In fact, Health Canada recently released 
important safety information warning about 
concerns with the 40 mg dose.7  The 40 mg 
dosage must not be used in patients who have pre-
existing medical conditions or other factors which 
put them at increased risk for rhabdomyolysis.  
This includes Asian ethnicity, serious kidney or 
liver problems, concomitant use with fibrates or 
niacin, hypothyroidism, situations where 
increased Crestor blood levels may occur, 
personal or family history of hereditary muscle 
problems, previous history of statin-induced 
muscle toxicity, and alcohol abuse.  Patients 
should be maintained on the lowest dose meeting 
their therapeutic goal.  For Asian patients and all 
patients with severe renal impairment (CLcr <30 
mL/min/1.73m2), a starting dosage of 5 mg once 
daily is recommended.  The 5 mg dose should be 
considered for all patients requiring less 
aggressive LDL-C reductions and those with 
predisposing factors for myopathy.7,8 
Meridia (sibutramine) for weight loss can 
increase blood pressure and also heart rate.  Obese 
patients may already present with underlying heart 
and vascular problems so caution in prescribing is 
essential.  Meridia is under scrutiny from Public 
Citizen because of these potentially dangerous 
side effects.9  Tell patients to check their blood 
pressure and heart rate regularly, and report any 
abnormal increases.  Emphasize healthy lifestyle 
changes.10 
Xenical (orlistat) decreases the amount of fat 
that is absorbed into the body.  But blocking 
absorption of fat can result in loose, oily stools 
and diarrhea.  Other side effects include stomach 
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cramping, pancreatitis, and vitamin deficiencies.  
Make sure patients who take Xenical divide their 
daily fat intake evenly over their three main meals 
and take a multivitamin that contains vitamins D, 
E, K, and beta-carotene.  This multivitamin 
should be taken at least two hours before or after 
taking Xenical.11 
Zyban (bupropion) is a non-nicotine medicine 
approved for smoking cessation.  Zyban reduces 
the nicotine withdrawal symptoms and the urge to 
smoke.  It is more effective when patients 
combine it with a patient support program.   
However, there is concern about a number of 
side effects.5  Rarely, patients who are taking 
Zyban have had heart attacks.  But, smokers are at 
high risk for cardiovascular disease and it is 
difficult to establish causality between Zyban and 
the heart attack.  Other side effects include 
thoughts of suicide or suicide attempts and 
seizures.    
Because of the possibility of seizures, patients 
who have a history of a seizure disorder, an eating 
disorder such as bulimia or anorexia nervosa, or 
are discontinuing the use of alcohol or sedatives 
should not receive Zyban, since these conditions 
may increase the chance of seizures while taking 
Zyban.  Also, when used for smoking cessation, 
the dose should not exceed 150 mg twice a day.  
As with the serotonin reuptake inhibitor 
antidepressants, patients and their families should 
watch for depression;  thoughts of suicide; or 
feelings of anxiety, irritability, hostility, severe 
restlessness, mania, or insomnia.  Finally, blood 
pressure should be closely monitored, especially if 
Zyban is being used concomitantly with a nicotine 
patch.12  
Serotonin reuptake inhibitors (SSRIs) 
antidepressants [such as Paxil (paroxetine), 
Prozac (fluoxetine) and others] are approved for 
use for anxiety and depression.  However, there is 
a growing list of use in off-label populations such 
as children and adolescents, and for a variety of 
off-label uses such as weight loss, incontinence, 
alcoholism, cocaine dependence, migraines, pain, 
fibromyalgia, irritable bowel syndrome, 
compulsive shopping, and many others.  With the 
increasing use in a broader range of patients, 
concern that use of these antidepressants can lead 
to an increased risk of aggression, violence, and 
suicide has surfaced.   
Patients, and families of patients taking an 
SSRI antidepressant, should watch for any of the 
following symptoms and if they occur, report 
them immediately: thoughts of suicide or suicide 
attempt; new or worsening depression or anxiety; 
agitation or irritability; acting aggressively, 
violently or in a dangerous manner, mania in 
actions and talking; or any other unusual 
behavior.13 
Bextra (valdecoxib) had new warnings added 
this December 2004.  Serious skin rashes such as 
toxic epidermal necrolysis, Stevens-Johnson 
syndrome, and erythema multiforme can occur 
anytime but usually occur within the first two 
weeks of therapy.  Advise patients to watch for 
rashes, lesions, or unusual swelling and 
discontinue Bextra at the first sign of these.  They 
should immediately call their health care 
professional when this occurs.  Additionally, 
Bextra is contraindicated for the treatment of post-
coronary bypass surgery (CABG) pain.  In this 
group of patients, Bextra is contraindicated due to 
cardiovascular thromboembolic adverse events.  A 
new bolded warning is being added to the label.  
Caution should be used when using Bextra in 
patients with ischaemic heart disease or other 
factors that may predispose to cardiovascular 
events such as congestive heart failure, unstable 
angina, uncontrolled hypertension, myocardial 
infarction, transient ischaemic attacks, and 
stroke.14  On April 7, 2005 Health Canada 
requested that Pfizer withdraw Bextra from the 
market.17  For more information on Bextra’s 
withdrawal go to: http://www.hc-
sc.gc.ca/english/protection/warnings/2005/2005
_17.html. 
Celebrex (celecoxib).  On December 17, 2004, 
Pfizer issued a news release that in the Adenoma 
Prevention with Celecoxib (APC) trial, patients 
taking 400 mg and 800 mg of Celebrex daily had 
an approximately 2.5 fold increase in major fatal 
or non-fatal cardiovascular events compared with 
placebo.  As a result of this finding, the APC 
colon cancer prevention trial was stopped.  
Though higher-than-recommended doses were 
used in the trial, these findings further raise safety 
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April 7, 2005 Health Canada announced new 
restrictions concerning the use of Celebrex.17  
These are:  
• Patients who have had a heart attack or 
stroke, experienced serious chest pain 
related to heart disease, or who have had 
serious diseases of the heart such as 
congestive heart failure, should NOT use 
this medication 
• Patients who have significant risk factors 
for heart attack or stroke should be aware 
that using this drug may increase this risk 
• This medication should be prescribed and 
used at the lowest possible dose, and for 
the shortest, necessary period of time  
• Selective COX-2 inhibitor NSAIDs should 
only be used to treat the pain and 
inflammation of arthritis, and certain types 
of acute pain 
On December 20, 2004, the FDA issued a 
patient advisory statement on naproxen (Aleve, 
Naprosyn) which can be bought over-the-counter 
in the U.S.  Preliminary information from an 
Alzheimer’s disease study showed some evidence 
of increased risk of cardiovascular events in 
patients taking naproxen.  The FDA advises that 
patients should not exceed the recommended dose 
of 220 mg twice daily for longer than ten days 
unless a physician directs otherwise.16 
Active involvement by patients in managing 
their medication with their health care 
professionals will minimize the dangerous effects 




Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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